

In re patent application of:

Farzan, et al.

Appl. No.: 10/772,089

Filed: February 5, 2004

For: Peptides Binding gp120 of HIV-1

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7570/80968

Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, MS Missing Parts
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents are also enclosed.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe any fees are due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7570/80968.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Michael A. Sanzo

Reg. No. 36,912

Attorney for Applicants

Date

May 25 , 200

1801 K Street, New., Suite 401L Washington, DC 20006-1201

Phone: (202) 419-7013

(O 1 F	4.3		Т		
MAY 2 6 2	004 E		. Atty. Docket No.: 7570/80968	Appl. No.: 10/772,089	
	:≥/	ERENCES CITED BY APPLICANT Use several sheets if necessary)	Applicant(s) Farzan, et al.		
MADE			Filing Date: February 5, 2004	Group: to be assigned	
Examiner Initial		OTHER PRIOR ART (Incl	uding Author, Title, Date, Pertinent Pages, Etc.)		
	Сl	BERGER, "HIV Entry and Tropism: The Chemokine Receptor Connection," <i>AIDS 11(Supp. A)</i> :S3-S16 (1997). COLE, et al., "Characterization of Neutralization Epitopes of Simian Immunodeficiency Virus (SIV) Recognized by Rhesus Monoclonal Antibodies Derived from Monkeys Infected with an Attenuated SIV Strain," <i>Virology 290</i> :59-73 (2001).			
	C 2				
	C 3	HIV-1 Envelope Glycoprotein gp120," Proc. Natl. Acad. Sci. USA 97:5762-5767 (2000).			
	C 4				
	C 5	DORANZ, et al., "Chemokine Receptors as Fusion Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1)," Immunologic Research 16:15-28 (1997).			
	C 6 DRAGIC, et al., "HIV-1 Entry into CDR ⁺ Cells Is Mediated by the Chemokine Receptor CC-CKR-5," Nature . 381:667-673 (1996). C 7 FARZAN, et al., "A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5," J. Virol. 72:1160-1164 (1998).				
	C 8	FARZAN, et al., "A Tyrosine-Sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-Enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry," J. Biol. Chem. 275:33516-33521 (2000). FOUTS, et al., "Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex," J. Virol. 71:2779-2785 (1997).			
	C 9				
	C 10				
	C 11				
	C 12				
	C 13				
	C 14				
	C 15				
	C 16			·	
	C 17				
	C 18				
Examiner			Date Considered		